Research On The Working Capital Management Efficiency Based On "Blood Supplementation" By Ruikang Pharmaceutical

With the promulgation of the medical reform policy,the market interest is tempting.At present,the pharmaceutical circulation enterprises in China's A-share market are rapidly increasing and the market competition is fierce.As a capital-intensive pharmaceutical distribution company,the daily business is to purchase medicines from upstream pharmaceutical manufacturing companies and sell them to downstream customers.However,due to the special nature of the distribution industry and the characteristics of the Chinese pharmaceutical market,pharmaceutical distribution companies are suffering from upstream and downstream suppliers and downstream sales terminals.Their capital requirements are very strict.Under this background,this article selects Ruikang Pharmaceutical,a leading enterprise in the pharmaceutical circulation industry of Shandong Province,as the research object,and takes the company as a starting point for increasing the number of blood supplements,using literature research,comparative analysis,and case studies.The traditional elements make horizontal and vertical comparative analysis of Ruikang's financial data.The most direct effect of the increase in "blood supplement" on working capital is the expansion of the scale of corporate working capital,adjustment of internal structure,changes in turnover period,and increase or decrease in cash flow.Changes in the above factors will eventually affect the earnings and risks of working capital management,and thus determine the efficiency of Ruikang's working capital management.This article is based on the increase in "blood",which will lead to the analysis of the size of the working capital,internal structure,turnover period and cash flow that will have the most direct impact on the growth of Ruikang Pharmaceutical.Secondly,the final impact of the above factors,resulting in Ruikang Pharmaceutical's working capital management of income and risk trends analysis.This article also innovatively combines the quality of corporate earnings with profitability analysis to explore the level of profitability behind Ruikang's profitability.Finally,based on the analysis results in the previous chapter of the article,we summarized the management efficiency of Ruikang Pharmaceutical's working capital,analyzed the causes of theproblems,and proposed countermeasures and suggestions for improving management efficiency in light of the problems presented.Through the study of Rui Kang's twice-increased “blood-enrichment” case,it is hoped that enterprises will pay attention to the management of working capital and must not blindly increase.Enterprises should take effective measures to improve the efficiency of business capital management,improve the level of business management,maximize the value of the company,and better participate in market competition.At the same time also hope to get reference and promotion in the same industry.